A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study)

✍ Scribed by LeCaer, H.; Greillier, L.; Corre, R.; Jullian, H.; Crequit, J.; Falchero, L.; Dujon, C.; Berard, H.; Vergnenegre, A.; Chouaid, C.

• Book ID: 119320765
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 268 KB
• Volume: 77
• Category: Article
• ISSN: 0169-5002
• DOI: 10.1016/j.lungcan.2012.02.004